63 related articles for article (PubMed ID: 28830206)
41. Emerging role of HMGB1 in fibrotic diseases.
Li LC; Gao J; Li J
J Cell Mol Med; 2014 Dec; 18(12):2331-9. PubMed ID: 25284457
[TBL] [Abstract][Full Text] [Related]
42. Inflammatory response and immune regulation of high mobility group box-1 protein in treatment of sepsis.
Liu QY; Yao YM
World J Emerg Med; 2010; 1(2):93-8. PubMed ID: 25214948
[TBL] [Abstract][Full Text] [Related]
43. Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials.
Mangla B; Javed S; Sultan MH; Kumar P; Kohli K; Najmi A; Alhazmi HA; Al Bratty M; Ahsan W
Phytother Res; 2021 Oct; 35(10):5440-5458. PubMed ID: 34184327
[TBL] [Abstract][Full Text] [Related]
44. Breast Cancer Prevention-Is there a Future for Sulforaphane and Its Analogs?
Kuran D; Pogorzelska A; Wiktorska K
Nutrients; 2020 May; 12(6):. PubMed ID: 32471217
[TBL] [Abstract][Full Text] [Related]
45. Potential of Sulforaphane as a Natural Immune System Enhancer: A Review.
Mahn A; Castillo A
Molecules; 2021 Feb; 26(3):. PubMed ID: 33535560
[TBL] [Abstract][Full Text] [Related]
46. High mobility group box 1 protein, a cue for stem cell recruitment.
Palumbo R; Bianchi ME
Biochem Pharmacol; 2004 Sep; 68(6):1165-70. PubMed ID: 15313414
[TBL] [Abstract][Full Text] [Related]
47. Emerging role of high-mobility group box 1 (HMGB1) in liver diseases.
Chen R; Hou W; Zhang Q; Kang R; Fan XG; Tang D
Mol Med; 2013 Nov; 19(1):357-66. PubMed ID: 24306421
[TBL] [Abstract][Full Text] [Related]
48. Endothelial barrier dysfunction in septic shock.
Opal SM; van der Poll T
J Intern Med; 2015 Mar; 277(3):277-293. PubMed ID: 25418337
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic potential of sulforaphane in liver diseases: a review.
Yan L; Yan Y
Front Pharmacol; 2023; 14():1256029. PubMed ID: 37705537
[TBL] [Abstract][Full Text] [Related]
50. HMGB1 in hormone-related cancer: a potential therapeutic target.
Srinivasan M; Banerjee S; Palmer A; Zheng G; Chen A; Bosland MC; Kajdacsy-Balla A; Kalyanasundaram R; Munirathinam G
Horm Cancer; 2014 Jun; 5(3):127-39. PubMed ID: 24718937
[TBL] [Abstract][Full Text] [Related]
51. Breaking the bond between tetranectin and HMGB1 in sepsis.
Paterson CW; Ford ML; Coopersmith CM
Sci Transl Med; 2020 Apr; 12(539):. PubMed ID: 32295899
[TBL] [Abstract][Full Text] [Related]
52. A two-decade journey in identifying high mobility group box 1 (HMGB1) and procathepsin L (pCTS-L) as potential therapeutic targets for sepsis.
Li J; Zhu CS; He L; Qiang X; Chen W; Wang H
Expert Opin Ther Targets; 2023; 27(7):575-591. PubMed ID: 37477229
[TBL] [Abstract][Full Text] [Related]
53. Experimental therapeutic strategies for severe sepsis: mediators and mechanisms.
Parrish WR; Gallowitsch-Puerta M; Czura CJ; Tracey KJ
Ann N Y Acad Sci; 2008 Nov; 1144():210-36. PubMed ID: 19076379
[TBL] [Abstract][Full Text] [Related]
54. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.
Srikrishna G; Freeze HH
Neoplasia; 2009 Jul; 11(7):615-28. PubMed ID: 19568407
[TBL] [Abstract][Full Text] [Related]
55. The potential use of l-sulforaphane for the treatment of chronic inflammatory diseases: A review of the clinical evidence.
Mazarakis N; Snibson K; Licciardi PV; Karagiannis TC
Clin Nutr; 2020 Mar; 39(3):664-675. PubMed ID: 30954362
[TBL] [Abstract][Full Text] [Related]
56. Plant sources, extraction techniques, analytical methods, bioactivity, and bioavailability of sulforaphane: a review.
Men X; Han X; Oh G; Im JH; Lim JS; Cho GH; Choi SI; Lee OH
Food Sci Biotechnol; 2024 Feb; 33(3):539-556. PubMed ID: 38274178
[TBL] [Abstract][Full Text] [Related]
57. Time to Develop Therapeutic Antibodies Against Harmless Proteins Colluding with Sepsis Mediators?
Li J; Bao G; Wang H
Immunotargets Ther; 2020; 9():157-166. PubMed ID: 33117741
[TBL] [Abstract][Full Text] [Related]
58. Management of sepsis.
Mackenzie I; Lever A
BMJ; 2007 Nov; 335(7626):929-32. PubMed ID: 17974689
[No Abstract] [Full Text] [Related]
59. Sulforaphane Reduces HMGB1-Mediated Septic Responses and Improves Survival Rate in Septic Mice.
Lee IC; Kim DY; Bae JS
Am J Chin Med; 2017; 45(6):1253-1271. PubMed ID: 28830206
[TBL] [Abstract][Full Text] [Related]
60. Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer - contradictory effects and future perspectives.
Jabbarzadeh Kaboli P; Afzalipour Khoshkbejari M; Mohammadi M; Abiri A; Mokhtarian R; Vazifemand R; Amanollahi S; Yazdi Sani S; Li M; Zhao Y; Wu X; Shen J; Cho CH; Xiao Z
Biomed Pharmacother; 2020 Jan; 121():109635. PubMed ID: 31739165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
